Search research articles
Contact Us
Filters
Showing results (81-90 of 110) with videos related to
Page
of 11
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
February 7, 2025
Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications
Taroh Satoh, Philippe Barthélémy, Lucia Nogova, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
April 2, 2018
Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma
David B Nelson, Rajeev Dhupar, Riham Katkhuda, et al.
The Oncologist
|
December 4, 2020
Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer
Stefano Cascinu, György Bodoky, Kei Muro, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 24, 2004
Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery
Jing Jin, Zhongxing Liao, Zhen Zhang, et al.
Molecular Cancer Therapeutics
|
October 14, 2011
Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models
Jae-Ho Cheong, Eun Sung Park, Jiyong Liang, et al.
Biorxiv : the Preprint Server for Biology
|
April 27, 2026
ARID1A deficiency unleashes centromeric RNA transcription to drive chromosomal instability and boosts PKMYT1 inhibitor efficacy via RNA sensing
Chengguo Li, Xueqian Cheng, Weizhen Liu, et al.
The Lancet. Oncology
|
June 5, 2025
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study
Elena Elimova, Jaffer Ajani, Howard Burris, et al.
The Lancet. Oncology
|
September 22, 2014
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke, Kei Muro, Eric Van Cutsem, et al.
The Lancet. Oncology
|
December 25, 2025
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial
Jong-Mu Sun, Yee Chao, Sung-Bae Kim, et al.
Journal of Geriatric Oncology
|
November 10, 2021
The association of age with acute toxicities in NRG oncology combined modality lower GI cancer trials
Noam VanderWalde, Jennifer Moughan, Stuart M Lichtman, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 110) with videos related to
Sort By:
Page
of 11
European Journal of Cancer (Oxford, England : 1990)
|
February 7, 2025
Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications
Taroh Satoh, Philippe Barthélémy, Lucia Nogova, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
April 2, 2018
Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma
David B Nelson, Rajeev Dhupar, Riham Katkhuda, et al.
The Oncologist
|
December 4, 2020
Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer
Stefano Cascinu, György Bodoky, Kei Muro, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 24, 2004
Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery
Jing Jin, Zhongxing Liao, Zhen Zhang, et al.
Molecular Cancer Therapeutics
|
October 14, 2011
Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models
Jae-Ho Cheong, Eun Sung Park, Jiyong Liang, et al.
Biorxiv : the Preprint Server for Biology
|
April 27, 2026
ARID1A deficiency unleashes centromeric RNA transcription to drive chromosomal instability and boosts PKMYT1 inhibitor efficacy via RNA sensing
Chengguo Li, Xueqian Cheng, Weizhen Liu, et al.
The Lancet. Oncology
|
June 5, 2025
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study
Elena Elimova, Jaffer Ajani, Howard Burris, et al.
The Lancet. Oncology
|
September 22, 2014
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke, Kei Muro, Eric Van Cutsem, et al.
The Lancet. Oncology
|
December 25, 2025
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial
Jong-Mu Sun, Yee Chao, Sung-Bae Kim, et al.
Journal of Geriatric Oncology
|
November 10, 2021
The association of age with acute toxicities in NRG oncology combined modality lower GI cancer trials
Noam VanderWalde, Jennifer Moughan, Stuart M Lichtman, et al.
Page
of 11